Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin
- PMID: 19483652
- DOI: 10.1097/CJI.0b013e3181a6981c
Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin
Abstract
The clinical development of immunotoxins in the treatment of solid tumors has been impeded in part, by the induction of an immune response directed primarily against the toxin moiety. Bouganin, a type I ribosome inactivating protein isolated from the leaf of Bougainvillea spectabilis Willd, was mutated to remove the T-cell epitopes while preserving the biological activity of the wild-type molecule. The T-cell epitope-depleted variant of bouganin (de-bouganin) was genetically linked to an anti-epithelial cell adhesion molecule (EpCAM) Fab moiety via a peptidic linker containing a furin proteolytic site to create the fusion construct VB6-845. To determine the optimal construct design for VB6-845, several dicistronic units where de-bouganin was genetically linked to either the N-terminal or C-terminal of either the heavy or light chain were engineered. Only the C-terminal variants expressed the full-length molecule. An in vitro assessment of the biological activity of VB6-845 showed that it bound and selectively killed EpCAM-positive cell lines with a greater potency than many commonly used chemotherapeutic agents. In vivo efficacy was demonstrated using an EpCAM-positive human tumor xenograft model in SCID mice with the majority of the mice treated being tumor free at the end of the study.
Similar articles
-
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.Cancer Res. 2009 Dec 1;69(23):8987-95. doi: 10.1158/0008-5472.CAN-09-2693. Epub 2009 Nov 24. Cancer Res. 2009. PMID: 19934334
-
Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.Br J Cancer. 2001 Feb;84(4):571-8. doi: 10.1054/bjoc.2000.1633. Br J Cancer. 2001. PMID: 11207056 Free PMC article.
-
Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.Leukemia. 1993 Feb;7(2):290-7. Leukemia. 1993. PMID: 7678881
-
Bouganin, an Attractive Weapon for Immunotoxins.Toxins (Basel). 2018 Aug 8;10(8):323. doi: 10.3390/toxins10080323. Toxins (Basel). 2018. PMID: 30096764 Free PMC article. Review.
-
Cell-targeting fusion constructs containing recombinant gelonin.Methods Enzymol. 2012;502:167-214. doi: 10.1016/B978-0-12-416039-2.00008-2. Methods Enzymol. 2012. PMID: 22208986 Review.
Cited by
-
Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.J Cancer Res Clin Oncol. 2015 Dec;141(12):2079-95. doi: 10.1007/s00432-015-1975-5. Epub 2015 Apr 22. J Cancer Res Clin Oncol. 2015. PMID: 25899161
-
Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5085-E5093. doi: 10.1073/pnas.1621233114. Epub 2017 Jun 12. Proc Natl Acad Sci U S A. 2017. PMID: 28607051 Free PMC article.
-
Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads.Biotechnol Bioeng. 2015 Jul;112(7):1306-18. doi: 10.1002/bit.25554. Epub 2015 Feb 23. Biotechnol Bioeng. 2015. PMID: 25655032 Free PMC article.
-
Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Mol Ther Methods Clin Dev. 2015 Jun 17;2:15021. doi: 10.1038/mtm.2015.21. eCollection 2015. Mol Ther Methods Clin Dev. 2015. PMID: 26151066 Free PMC article.
-
FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.Blood Adv. 2018 Feb 27;2(4):309-322. doi: 10.1182/bloodadvances.2017013482. Blood Adv. 2018. PMID: 29444872 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous